Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Solida

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Translational Psychiatry|July 6, 2021
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Translational Psychiatry|October 8, 2021
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 16, 2007
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patientsSuzie Lavoie, Micah M Murray, Patricia Deppen, et al.
Early Intervention in Psychiatry|April 27, 2024
Pathways to care in youth and young adults at clinical high risk for psychosis in Switzerland: Current situation and clinical implementation of the PsyYoung projectBarbara Bailey, Alessandra Solida, Christina Andreou, et al.
Imaging Neuroscience (Cambridge, Mass.)|June 22, 2026
High-resolution whole-brain magnetic resonance spectroscopic imaging in youth at risk for psychosisEdgar Céléreau, Federico Lucchetti, Yasser Alemán-Gómez, et al.
Journal of Clinical Lipidology|November 13, 2017
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemiaAurélie Delacrétaz, Frederik Vandenberghe, Mehdi Gholam-Rezaee, et al.
L'Encephale|February 18, 2026
[The romande fidelity scale for early intervention in psychosis]Luis Alameda, Caroline Conchon, Élodie Sprüngli-Toffel, et al.
Journal of Clinical Medicine|July 29, 2023
Improving Pathways to Care for Patients at High Psychosis Risk in Switzerland: PsyYoung Study ProtocolCaroline Conchon, Elodie Sprüngli-Toffel, Luis Alameda, et al.
Spanish Journal of Psychiatry and Mental Health|September 20, 2024
Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disordersElodie Sprüngli-Toffel, Erich Studerus, Logos Curtis, et al.
American Journal of Human Genetics|July 19, 2011
VPS35 mutations in Parkinson diseaseCarles Vilariño-Güell, Christian Wider, Owen A Ross, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Translational Psychiatry|July 6, 2021
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Translational Psychiatry|October 8, 2021
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 16, 2007
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patientsSuzie Lavoie, Micah M Murray, Patricia Deppen, et al.
Early Intervention in Psychiatry|April 27, 2024
Pathways to care in youth and young adults at clinical high risk for psychosis in Switzerland: Current situation and clinical implementation of the PsyYoung projectBarbara Bailey, Alessandra Solida, Christina Andreou, et al.
Imaging Neuroscience (Cambridge, Mass.)|June 22, 2026
High-resolution whole-brain magnetic resonance spectroscopic imaging in youth at risk for psychosisEdgar Céléreau, Federico Lucchetti, Yasser Alemán-Gómez, et al.
Journal of Clinical Lipidology|November 13, 2017
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemiaAurélie Delacrétaz, Frederik Vandenberghe, Mehdi Gholam-Rezaee, et al.
L'Encephale|February 18, 2026
[The romande fidelity scale for early intervention in psychosis]Luis Alameda, Caroline Conchon, Élodie Sprüngli-Toffel, et al.
Journal of Clinical Medicine|July 29, 2023
Improving Pathways to Care for Patients at High Psychosis Risk in Switzerland: PsyYoung Study ProtocolCaroline Conchon, Elodie Sprüngli-Toffel, Luis Alameda, et al.
Spanish Journal of Psychiatry and Mental Health|September 20, 2024
Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disordersElodie Sprüngli-Toffel, Erich Studerus, Logos Curtis, et al.
American Journal of Human Genetics|July 19, 2011
VPS35 mutations in Parkinson diseaseCarles Vilariño-Güell, Christian Wider, Owen A Ross, et al.
Pageof 4